Hepatitis D Trials

*CHB=Chronic hepatitis B, HBD=hepatitis D

For trials listed as "International" or "International Only," click on the NCT identification number for a complete list of participating countries.

Evaluation of Patients with Liver Disease, Including Hepatitis D – U.S.
Evaluate, investigate and follow-up patients suffering from acute and chronic liver disease. Qualified patients may be able to participate in other offered studies. Contact: Nancy Fryzek at 301-435-6122 nancy.fryzek@nih.gov or Dr. T. Jake Liang at 301-496-1721 jakel@mail.nih.gov. Refer to identifier NCT00001971 (Study ID # 910214, 91-DK-0214)

The Hepatitis Delta International Network –International
Multicenter, observational study (patients will not receive any treatment) that will build a registry of HDV patients around the world and collect clinical information. Contact: Dr. Heiner Wedemeyer at Wedemeyer.Heiner@mh-hannover.de or Dr. SvenjaHardtke at Hardtke.Svenja@mh-hannover.de and refer to identifier NCT02375906 (Study ID # HepNet-HDIN)

Currently recruiting patients in: 

  • Manaus, Brazil 
  • Rondonia, Brazil
  • Berlin, Germany
  • Hannover, Germany
  • Larissa, Greece
  • Karachi, Pakistan
  • Ankara, Turkey

Ezetimibe for Patients With Chronic Hepatitis D – Pakistan
Ezetimibe possesses pharmacophore features to inhibit NTCP, the receptor required for HBV and HDV hepatocyte entry that include two hydrophobes and one hydrogen bond acceptor. Therapy with ezetimibe may lead to decline in hepatitis D virus levels. The aim of the study is to evaluate the utility of ezetimibe in patients with chronic HDV infection. Contact: Zaigham Abbas at 922135862937 or email drzabbas@gmail.com and refer to identifier NCT03099278.